OTCM
ZLDAF
Market cap4mUSD
Oct 20, Last price
0.26USD
Name
Zelira Therapeutics Ltd
Chart & performance
P/E
—
P/S
7,431.59
EPS
—
Vol. 1Y
—
Shs. 5Y
18.82%
Rev. 5Y
-34.19%
Div Yld LY
—
Div Yld TTM
—
Revenues
1k
-99.31%
Net income
-4m
L-90.08%
CFO
-5m
L+11.81%
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Zelira Therapeutics Limited is an Australian biopharmaceutical company dedicated to the research, development, and commercialization of cannabinoid-derived therapeutic agents, aimed at treating a variety of medical conditions. The firm offers its HOPE brand formulations in Pennsylvania and Louisiana, and is actively developing Zenivol, a cannabinoid-based medicine specifically designed for chronic insomnia. Beyond its prescription products, Zelira also markets several over-the-counter (OTC) items, including SprinJene for oral care and RAF FIVE for dermatological applications. A notable OTC offering is ITURA, an advanced topical cream formulated to alleviate multiple symptoms such as numbness, tingling sensations, muscle cramps, reduced sensitivity, and pain frequently associated with Peripheral Artery Disease and diabetes. Zelira Therapeutics has cultivated strategic partnerships with prominent institutions, including Curtin University, the Telethon Kids Institute, the University of Western Australia, St. Vincent's Hospital, and the Children's Hospital of Philadelphia. Incorporated in 2003, the company, which officially changed its name from Zelda Therapeutics Limited in December 2019, maintains its corporate headquarters in Perth, Australia.
Key people
Chairman of the Board · since 2019
Oludare Odumosu
Global Chief Executive Officer and Managing Director · since 2021
Greg Blake
Executive Director · since 2023
Donna O'Donnell
Non-Executive Director · since 2023
Company Secretary, Non-Executive Director · since 2022
Legal address
c/o BLACKWALL LEGAL LLP, Level 26, 140 St GeorgesTerrace
Perth, WA 6000
AU
Perth, WA 6000
AU
Headquarters
Level 9 190 St Georges Tce
Perth, WA 6000
AU
Perth, WA 6000
AU
Valuation
Title AUD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|
| 2025‑06 | 2024‑06 | 2023‑06 | 2022‑06 | 2021‑06 | 2020‑06 | 2019‑06 | 2018‑06 | 2017‑06 | |
| Income | |||||||||
Revenues | |||||||||
Cost of revenue | |||||||||
Unusual Expense (Income) | |||||||||
NOPBT | |||||||||
NOPBT Margin | |||||||||
Operating Taxes | |||||||||
Tax Rate | |||||||||
NOPAT | |||||||||
Net income | |||||||||
Dividends | |||||||||
Dividend yield | |||||||||
Proceeds from repurchase of equity | |||||||||
BB yield | |||||||||
| Debt | |||||||||
Debt current | |||||||||
Long-term debt | |||||||||
Deferred revenue | |||||||||
Other long-term liabilities | |||||||||
Net debt | |||||||||
| Cash flow | |||||||||
Cash from operating activities | |||||||||
CAPEX | |||||||||
Cash from investing activities | |||||||||
Cash from financing activities | |||||||||
FCF | |||||||||
| Balance | |||||||||
Cash | |||||||||
Long term investments | |||||||||
Excess cash | |||||||||
Stockholders' equity | |||||||||
Invested Capital | |||||||||
ROIC | |||||||||
ROCE | |||||||||
| EV | |||||||||
Common stock shares outstanding | |||||||||
Price | |||||||||
Market cap | |||||||||
EV | |||||||||
EBITDA | |||||||||
EV/EBITDA | |||||||||
Interest | |||||||||
Interest/NOPBT | |||||||||